Zacks Investment Research cut shares of MyoKardia, Inc. (NASDAQ:MYOK) from a hold rating to a sell rating in a report published on Wednesday morning.
According to Zacks, “MyoKardia, Inc. is a biopharmaceutical company. The company focuses on discovering, developing, and commercializing therapies for the treatment of serious and neglected rare cardiovascular diseases. Its product candidate consists of MYK-461, a small molecule to reduce excessive cardiac muscle contractility leading to hypertrophic cardiomyopathy, DCM-1, treats heritable dilated cardiomyopathy by restoring normal contractility in the diseased DCM heart, HCM-2, a product candidate to reduce cardiac muscle contractility to normal levels in HCM patients and LUS-1, which is intended to counteract a muscle disruption that results in impaired relaxation of the heart, which are in different clinical trial. MyoKardia, Inc. is headquartered in San Francisco, California. “
Other equities analysts also recently issued reports about the stock. BMO Capital Markets reissued a buy rating and issued a $45.00 price target (up from $32.00) on shares of MyoKardia in a report on Tuesday, August 8th. ValuEngine raised shares of MyoKardia from a sell rating to a hold rating in a report on Monday, August 7th. TheStreet raised shares of MyoKardia from a d+ rating to a c rating in a report on Thursday, July 6th. Wedbush reissued an outperform rating and issued a $51.00 price target on shares of MyoKardia in a report on Wednesday, September 20th. Finally, Credit Suisse Group reissued an outperform rating and issued a $55.00 price target (up from $45.00) on shares of MyoKardia in a report on Tuesday, September 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the stock. The company presently has an average rating of Buy and a consensus price target of $55.00.
MyoKardia (NASDAQ:MYOK) last posted its quarterly earnings data on Monday, August 7th. The biotechnology company reported ($0.41) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.37) by ($0.04). The firm had revenue of $5.60 million for the quarter, compared to analysts’ expectations of $6.73 million. MyoKardia had a negative return on equity of 16.35% and a negative net margin of 44.65%. MyoKardia’s revenue was up 60.0% compared to the same quarter last year. During the same period in the prior year, the firm earned ($0.37) earnings per share. On average, analysts anticipate that MyoKardia will post ($1.63) EPS for the current year.
ILLEGAL ACTIVITY WARNING: “MyoKardia, Inc. (MYOK) Downgraded by Zacks Investment Research to Sell” was first posted by Community Financial News and is owned by of Community Financial News. If you are reading this news story on another domain, it was stolen and reposted in violation of US & international trademark & copyright law. The original version of this news story can be accessed at https://www.com-unik.info/2017/10/12/myokardia-inc-myok-downgraded-by-zacks-investment-research-to-sell.html.
In other news, Director Wendy L. Yarno acquired 1,408 shares of the stock in a transaction that occurred on Monday, August 14th. The shares were acquired at an average cost of $35.50 per share, for a total transaction of $49,984.00. Following the purchase, the director now owns 1,408 shares of the company’s stock, valued at approximately $49,984. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Anastasios Gianakakos sold 4,300 shares of the business’s stock in a transaction dated Wednesday, October 4th. The shares were sold at an average price of $40.86, for a total value of $175,698.00. The disclosure for this sale can be found here. Insiders sold a total of 1,786,501 shares of company stock worth $74,371,815 over the last 90 days. 33.40% of the stock is currently owned by company insiders.
A number of institutional investors have recently made changes to their positions in MYOK. Nationwide Fund Advisors raised its stake in MyoKardia by 36.3% in the 2nd quarter. Nationwide Fund Advisors now owns 9,729 shares of the biotechnology company’s stock valued at $127,000 after acquiring an additional 2,591 shares during the period. Highbridge Capital Management LLC bought a new stake in MyoKardia in the 1st quarter valued at about $136,000. Alliancebernstein L.P. bought a new stake in MyoKardia in the 2nd quarter valued at about $148,000. State of Wisconsin Investment Board bought a new stake in MyoKardia in the 2nd quarter valued at about $157,000. Finally, The Manufacturers Life Insurance Company raised its stake in MyoKardia by 38.8% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 15,073 shares of the biotechnology company’s stock valued at $198,000 after acquiring an additional 4,215 shares during the period. Institutional investors and hedge funds own 42.94% of the company’s stock.
MyoKardia, Inc is a clinical-stage biopharmaceutical company. The Company focuses on the treatment of heritable cardiomyopathies, a group of rare, genetically-driven forms of heart failure that result from biomechanical defects in cardiac muscle contraction. The Company is engaged in the business of developing and commercializing therapeutics.
What are top analysts saying about MyoKardia Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for MyoKardia Inc. and related companies.